Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

Obinutuzumab is a glycoengineered, type 2 anti-CD20 humanized antibody with single-agent activity in relapsed chronic lymphocytic leukemia (CLL). With other CD20 antibodies, a dose-response relationship has been shown. We therefore performed a randomized phase 2 study in symptomatic, untreated CLL p...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Byrd, John C., Flynn, Joseph M., Kipps, Thomas J., Boxer, Michael, Kolibaba, Kathryn S., Carlile, David J., Fingerle-Rowson, Guenter, Tyson, Nicola, Hirata, Jamie, Sharman, Jeff P.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2016
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4705612/
https://ncbi.nlm.nih.gov/pubmed/26472752
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-03-634394
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars